Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.

NCT Number	NCT06989723
Lead Sponsor	Seoul National University Bundang Hospital Collaborators: Celltrion
Conditions	Type 2 Diabetes, Fatty Liver
Enrollment	120 participants
Start Date	2025-01-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-25